UNSPSC 51351521: Anagestone acetate

This classification denotes a therapeutic progestin with the molecular formula C24H36O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier GNT396G9QT, chemically known as pregn-4-en-20-one, 17-hydroxy-6alpha-methyl-, acetate (8ci) but more generally known as anagestone acetate, which bears US NIH Compound Identifier 18443. European Medicines Agency schedules Anagestone acetate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00522MIG.

Most nations, for tariff and trade purposes, schedule anagestone acetate under HS 29372300 and SITC 54153. As of Q4 2014, ANAGESTONE ACETATE remains US FDA's Preferred Term for this commodity. Anagestone acetate bears US NLM identifiers UMLS ID C2698107 and NCI Concept Code C76302. SMILES: C[C@H]1C[C@@H]2[C@H](CC[C@]3([C@H]2CC[C@@]3(C(=O)C)OC(=O)C)C)[C@@]4(C1=CCCC4)C.

UNSPSC 51351521 Anagestone acetate is a Commodity code covering a pharmaceutical active pharmaceutical ingredient with minimal recent state and local procurement activity visible in the available records. State and local governments do not routinely procure pharmaceutical raw materials or API compounds directly; when they appear in procurement systems at all, they are typically embedded in finished-goods pharmaceutical contracts or purchased through health department bulk-purchasing vehicles and cooperative agreements. The code shows no recent opportunities in the current dataset.

Without visible recent solicitations, no geographic spread, issuing-body pattern, or representative procurement examples can be characterized from this source. If your firm supplies anagestone acetate to pharmaceutical manufacturers or contract packagers that serve state and local health systems or correctional agencies, the pathway would likely flow through a prime contractor rather than direct state or local RFP activity. Monitor state health department drug-purchasing consortia and prison-system pharmaceutical supply agreements for indirect opportunities.